- Why FIH Budgets Are Hard to Estimate Early
- The Major Cost Drivers in a Medical Device FIH Study
- How Program Structure Affects Total Cost
- Geography as a Budget Variable
- Common Budget Mistakes to Avoid
- Building a Budget That Fits Your Capital Cycle
- FAQs
Planning a clinical trial budget is one of the most consequential decisions a medical device startup makes before first-in-human work begins. Get it right, and you protect your runway while hitting the data milestone your next funding round depends on. Get it wrong, and you either burn cash on delays or arrive at your Series B with incomplete evidence.
This article breaks down the real cost drivers in a first-in-human (FIH) medical device study — where budgets tend to slip, and how geography and program structure affect what you actually spend.
Why FIH Budgets Are Hard to Estimate Early
Most founders underestimate FIH costs because they anchor on a single line item — usually the CRO fee — and treat everything else as rounding error. In practice, that fee is only one component of a budget that spans regulatory strategy, site operations, patient enrollment, data management, and submission preparation.
The other common mistake is treating a US-based CRO quote as the only benchmark. US and EU trial infrastructure carries a cost structure built for large pharma programs. When a startup with $2 million allocated for FIH work receives a quote sized for a 24-month, multi-site Phase I at a US academic medical center, the numbers rarely fit.
The Major Cost Drivers in a Medical Device FIH Study
1. Regulatory Strategy and Pre-Submission Work
Before a single patient is enrolled, you need a clear FDA pathway and a protocol that will generate data FDA will accept. That means Pre-Sub meetings, IDE preparation where applicable, and protocol architecture aligned to your 510(k), De Novo, PMA, or HDE route.
This workstream is consistently underbudgeted because it feels like planning rather than execution. But a protocol that misaligns with your intended regulatory pathway can force an amendment mid-study — and amendments cost both time and money. Solid regulatory strategy work at the front end is one of the most cost-efficient investments in the entire budget.
2. Ethics and Regulatory Approval Timelines
Approval timelines directly affect burn rate. Every month your study sits in a regulatory queue is a month of overhead, staff time, and deferred data.
In the US and EU, ethics and regulatory approvals typically take 6 to 12 months. In Panama, El Salvador, Chile, and the Dominican Republic, the same approvals are observed in 30 to 90 days. That difference alone can represent several hundred thousand dollars in carrying costs for a startup maintaining a standing team, device inventory, and site readiness while waiting.
Geography is a budget variable, not just a logistics preference.
3. Site Activation and Investigator Fees
Site activation covers site qualification, contract negotiation, ethics submissions at the site level, and investigator training. For a multi-site study, these costs multiply quickly.
Investigator fees vary significantly by country and specialty. Device trials requiring surgical implantation or specialized procedural skills command higher per-procedure fees than simpler interventional studies. Budgeting accurately here requires knowing your device category, the investigator profile the protocol demands, and the site's patient volume in your target indication.
Working with a network of pre-qualified sites reduces activation time and can lower the cost of feasibility work. A CRO with established site relationships doesn't need to rebuild that infrastructure from scratch for each new sponsor.
4. Patient Enrollment
Enrollment is where most FIH budgets experience their largest unplanned overruns. The primary causes are overly optimistic enrollment rate assumptions and underestimated screen failure rates.
Eligibility criteria in medical device FIH studies tend to be narrow. You may need a specific anatomical profile, disease severity range, or prior treatment history. Screen failure rates of 30 to 50 percent are common. If your budget assumes a one-to-one screening-to-enrollment ratio, you will run out of money before you hit your sample size.
Enrollment costs include patient stipends, screening visits, protocol-required diagnostics, and site staff time per patient contact. In jurisdictions with strong patient availability for your indication and experienced site coordinators, these costs are lower and enrollment moves faster.
5. Data Management and EDC
Electronic data capture setup, data entry, query resolution, and database lock are both fixed and variable costs that scale with protocol complexity and visit count. A lean protocol with fewer endpoints and fewer visits costs less to manage than a heavily instrumented study.
This is worth considering at the protocol design stage. Every additional data collection point adds cost downstream. Protocol authors who haven't managed data operations often add endpoints that sound useful but are expensive to collect and never appear in the final submission package.
6. Safety Monitoring and Adverse Event Reporting
For a first-in-human study, safety monitoring is non-negotiable. This includes a Data Safety Monitoring Board or equivalent independent review, Medical Monitor fees, and the infrastructure to capture, adjudicate, and report adverse events in compliance with ICH-GCP and ISO 14155 standards.
Adverse event reporting workflows that are well-structured from the outset cost less to operate than those assembled after enrollment begins.
7. Clinical Study Report and Submission Package
The end product of a FIH study is not raw data. It is a clinical study report and an organized data room structured for your next FDA regulatory step. Under FDA 21 CFR 812.28, foreign clinical data collected under the appropriate framework is accepted for US IDE and IND submissions — but the data must be organized and presented in a format FDA can use.
Sponsors who treat the CSR as an afterthought often face significant cost and time reconstructing documentation that should have been captured prospectively. Building the submission package into the program from day one keeps this cost predictable.
How Program Structure Affects Total Cost
The difference between a structured FIH program and a fragmented vendor approach is meaningful from a budget standpoint.
When a sponsor coordinates regulatory consultants, a CRO, a site management organization, a data management vendor, and a medical writer as separate contracts, they pay for the overhead of managing all those relationships. Each vendor has its own scope boundaries, change order process, and communication overhead. Gaps between vendor scopes become the sponsor's problem to resolve — and resolving them costs money.
A single-vendor program covering all workstreams under one engagement eliminates that coordination tax. It also makes the budget more predictable because scope is defined once, not renegotiated across five separate contracts.
bioaccess® structures its FIH-12™ program around nine workstreams managed by one accountable team — from FDA strategy alignment and protocol development through site activation, enrollment, data management, and final submission-ready evidence package delivery. The 12-month timeline is designed to fit within a startup's capital cycle between funding rounds.
Geography as a Budget Variable
Running a FIH study in the US or EU is not inherently more rigorous than running one in a jurisdiction with faster approvals. What matters is whether the data is collected under a framework FDA will accept and whether the protocol architecture meets the applicable standard.
Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US regulatory submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture, with ACRP-certified clinical operations, produce data that travels to FDA submissions.
The budget implication is direct. A 30 to 90-day approval window in Panama, El Salvador, Chile, or the Dominican Republic versus a 6 to 12-month window in the US means a faster enrollment start, lower carrying costs, and a submission-ready dataset delivered within a timeline that aligns with your next funding milestone.
Common Budget Mistakes to Avoid
Anchoring on a single line item. The CRO fee is visible; site costs, regulatory delays, and screen failure overruns are not. Budget for the full program, not just the contract.
Underestimating screen failures. Build a realistic screen failure assumption into your enrollment budget from the start. For most device FIH studies, plan for at least a 2:1 screening-to-enrollment ratio.
Treating submission preparation as separate. The CSR and data room are part of the study, not a separate project. If your budget doesn't include them, your total cost estimate is incomplete.
Ignoring approval timeline costs. A 9-month regulatory queue is not free. It carries a real cost in staff time, site readiness, and deferred data. Factor approval timelines into your total program cost, not just your CRO fee.
Choosing a CRO by lowest fee. A low CRO fee attached to a 24-month timeline and fragmented workstreams may cost more in total than a higher fee attached to a 12-month structured program with single-vendor accountability.
Building a Budget That Fits Your Capital Cycle
For seed-to-Series-B medical device startups, the FIH budget is not purely a clinical operations question — it is a capital strategy question. The goal is a submission-ready dataset before your next funding round closes, delivered within the $1 million to $5 million range most early-stage programs are working with.
That requires a program structure where timeline, scope, and cost are defined together, not independently. It requires a geography where approvals don't consume half your runway. And it requires a CRO that can deliver the full evidence package, not just enrollment.
The early-phase CRO services market reached USD 6.73 billion in 2026 per Mordor Intelligence, reflecting how central this decision has become for life sciences startups. Choosing the right program structure and jurisdiction is one of the highest-leverage decisions in that market.
If you are at the stage of building your FIH budget, the bioaccess® FIH Launch Planner generates a preliminary country route, timeline range, and evidence package estimate from six sponsor inputs — a practical starting point before you issue an RFP.
FAQs
What is a realistic budget range for a medical device FIH study?
Most medical device FIH studies at seed-to-Series-B startups fall in the $1 million to $5 million range, depending on device complexity, sample size, number of sites, and the jurisdiction where the study runs. This range covers regulatory strategy, site activation, enrollment, data management, and submission preparation.
Does running a FIH study in Latin America cost less than running one in the US?
Geography affects both direct costs and timeline costs. In Panama, El Salvador, Chile, and the Dominican Republic, regulatory approvals take 30 to 90 days versus 6 to 12 months in the US or EU. Faster approvals reduce carrying costs and get you to enrollment sooner, which affects total program cost in a meaningful way.
Will FDA accept data from a FIH study conducted in Latin America?
Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US IDE and IND submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture and conducted under ICH-GCP standards produce data that supports US regulatory submissions. FDA acceptance of foreign clinical data under this framework is not unconditional approval of the trial itself, but the pathway is well-established.
What causes FIH clinical trial budgets to overrun?
The most common causes are underestimated screen failure rates, regulatory approval delays that extend carrying costs, scope gaps between fragmented vendors, and treating submission preparation as a separate project rather than part of the study budget.
How does a single-vendor CRO program affect budget predictability?
When one team manages all workstreams under a single engagement, scope is defined once and change orders are less frequent. Fragmented vendor models require sponsors to manage scope boundaries across multiple contracts, which creates cost exposure that is difficult to budget in advance.
What is the minimum sample size for a medical device FIH study?
There is no universal minimum. Sample size depends on your regulatory pathway, the endpoints you need to support, and the statistical requirements of your protocol. IDE feasibility studies often enroll 10 to 30 subjects, while studies supporting a 510(k) or De Novo may require larger cohorts. Your protocol architecture and FDA pathway determine the number.
When should a startup start planning its FIH budget?
Ideally 12 to 24 months before you need first human data. That window allows time for regulatory strategy alignment, protocol development, site selection, and approval processes without compressing your timeline. Starting budget planning after IDE approval or a Series A close is common, but it leaves less margin for adjustment.
Planning your clinical trial budget well before you need it is not excessive caution — it is how startups protect their runway and arrive at their next funding milestone with the data they promised. The decisions you make on program structure, geography, and vendor accountability shape not just what you spend, but whether you spend it on time.
Leave a Reply